Long-term efficacy of weekly paclitaxel therapy in unresectable primary squamous cell carcinoma of the thyroid


      Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare disease with a poor prognosis. Because of its rarity, there is no established therapeutic regimen in unresectable cases. We report a case of PSCCT treated with weekly paclitaxel (wPTX) for more than 2 years. A 59-year-old woman presented to our hospital with a progressively enlarging neck mass. CT and MRI scans showed a tumor arising from the right lobe of the thyroid, invading the esophagus and trachea, as well as partially surrounding and invading the right common carotid artery. It was deemed unresectable. Biopsy revealed poorly differentiated squamous cell carcinoma. wPTX therapy was initiated. The patient achieved a partial response and is still undergoing treatment 28 months later. Adverse events included grade 3 neutropenia and grade 2 peripheral sensory neuropathy, which were manageable. Long-term wPTX therapy has been effective in this case of unresectable PSCCT.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wang W
        • Ouyang Q
        • Meng C
        • Jing L
        • Li X.
        Treatment optimization and prognostic considerations for primary squamous cell carcinoma of the thyroid.
        Gland Surg. 2019; 8: 683-690
        • Ito Y
        • Higashiyama T
        • Hirokawa M
        • Fukushima M
        • Kihara M
        • Takamura Y
        • et al.
        Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component.
        Endocr J. 2012; 59: 839-844
        • Yasumatsu R
        • Sato M
        • Uchi R
        • Nakano T
        • Hashimoto K
        • Kogo R
        • et al.
        The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid.
        Auris Nasus Larynx. 2018; 45: 553-557
        • Higashiyama T
        • Ito Y
        • Hirokawa M
        • Fukushima M
        • Uruno T
        • Miya A
        • et al.
        Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
        Thyroid. 2010; 20: 7-14
        • Onoda N
        • Sugino K
        • Higashiyama T
        • Kammori M
        • Toda K
        • Ito K
        • et al.
        The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study.
        Thyroid. 2016; 26: 1293-1299
        • Tahara M
        • Kiyota N
        • Yamazaki T
        • Chayahara N
        • Nakano K
        • Inagaki L
        • et al.
        Lenvatinib for Anaplastic Thyroid Cancer.
        Front Oncol. 2017; 7: 25
        • Okamoto T
        • Ito Y
        • Onoda N
        • Akasu T
        • Ito K
        • Uchino S
        • et al.
        Japanese Guidelines for Treatment of Thyroid Tumors 2018.
        Ofiicial Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery. 2018; 35
        • Tahara M
        • Minami H
        • Hasegawa Y
        • Tomita K
        • Watanabe A
        • Nibu K
        • et al.
        Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer.
        Cancer Chemother Pharmacol. 2011; 68: 769-776
        • Goldberg HM
        • Harvey P.
        Squamous-cell cysts of the thyroid with special reference to the aetiology of squamous epithelium in the human thyroid.
        Br J Surg. 1956; 43: 565-569
        • Chaudhary RK
        • Barnes EL
        • Myers EN.
        Squamous cell carcinoma arising in Hashimoto's thyroiditis.
        Head Neck. 1994; 16: 582-585
        • Kebapci N
        • Efe B
        • Kabukcuoglu S
        • Akalin A
        • Kebapci M.
        Diffuse sclerosing variant of papillary thyroid carcinoma with primary squamous cell carcinoma.
        J Endocrinol Invest. 2002; 25: 730-734
        • Koyama S
        • Fujiwara K
        • Nosaka K
        • Fukuhara T
        • Morisaki T
        • Miyake N
        • et al.
        Immunohistochemical Features of Primary Pure Squamous Cell Carcinoma in the Thyroid: An Autopsy Case.
        Case Rep Oncol. 2018; 11: 418-424
        • Tohyama O
        • Matsui J
        • Kodama K
        • Hata-Sugi N
        • Kimura T
        • Okamoto K
        • et al.
        Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
        J Thyroid Res. 2014; 2014
        • Wang J
        • Lou P
        • Lesniewski R
        • Henkin J.
        Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly.
        Anticancer Drugs. 2003; 14: 13-19
        • Gulubova M
        • Ivanova K
        • Ananiev J
        • Gerenova J
        • Zdraveski A
        • Stoyanov H
        • et al.
        VEGF expression, microvessel density and dendritic cell decrease in thyroid cancer.
        Biotechnol Biotechnol Equip. 2014; 28: 508-517
        • Del Rosario M
        • Dasanu C
        • Tsai H
        • Johnson R.
        Primary squamous cell carcinoma of the thyroid with complete response to radical radiotherapy and concurrent cisplatin-based chemotherapy.
        BMJ Case Rep. 2017; 2017